Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers. It affects younger women, women of African descent, and those with BRCA1 mutations. TNBC is highly complex, with distinct subtypes that may respond differently to treatments. Recent advancements include immunotherapies, androgen receptor inhibitors, platinum-based drugs, antibody-drug conjugates, PARP inhibitors, and combination therapies. These podcast episodes address educational gaps in TNBC management, offering interactive cases, discussions on emerging treatments, and strategies to improve patient outcomes.

Launch Date: December 5, 2024

Release Date: December 5, 2024

Expiration Date: November 30, 2025

FACULTY

Aditya Bardia, MD, MPH, FASCO

Associate Professor, Medicine, Harvard Medical School

Attending Physician, Medical Oncology, Massachusetts General Hospital

Dana-Farber/Harvard Cancer Center, Boston, MA

Rita Nanda, MD

Associate Professor of Medicine

Director, Breast Oncology Program

The University of Chicago Medicine Chicago, IL

his podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.

https://www.practicepointcme.com/CMEHome/talking-tnbc-advancing-treatment-in-triple-negative-breast-cancer-latest-insights-and-clinical-strategies-19

Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers. It affects younger women, women of African descent, and those with BRCA1 mutations. TNBC is highly complex, with distinct subtypes that may respond differently to treatments. Recent advancements include immunotherapies, androgen receptor inhibitors, platinum-based drugs, antibody-drug conjugates, PARP inhibitors, and combination therapies. These podcast episodes address educational gaps in TNBC management, offering interactive cases, discussions on emerging treatments, and strategies to improve patient outcomes.

Launch Date: December 5, 2024

Release Date: December 5, 2024

Expiration Date: November 30, 2025

FACULTY

Aditya Bardia, MD, MPH, FASCO

Associate Professor, Medicine, Harvard Medical School

Attending Physician, Medical Oncology, Massachusetts General Hospital

Dana-Farber/Harvard Cancer Center, Boston, MA

Rita Nanda, MD

Associate Professor of Medicine

Director, Breast Oncology Program

The University of Chicago Medicine Chicago, IL

his podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.

https://www.practicepointcme.com/CMEHome/talking-tnbc-advancing-treatment-in-triple-negative-breast-cancer-latest-insights-and-clinical-strategies-19

Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers. It affects younger women, women of African descent, and those with BRCA1 mutations. TNBC is highly complex, with distinct subtypes that may respond differently to treatments. Recent advancements include immunotherapies, androgen receptor inhibitors, platinum-based drugs, antibody-drug conjugates, PARP inhibitors, and combination therapies. These podcast episodes address educational gaps in TNBC management, offering interactive cases, discussions on emerging treatments, and strategies to improve patient outcomes.

Launch Date: December 5, 2024

Release Date: December 5, 2024

Expiration Date: November 30, 2025

FACULTY

Aditya Bardia, MD, MPH, FASCO

Associate Professor, Medicine, Harvard Medical School

Attending Physician, Medical Oncology, Massachusetts General Hospital

Dana-Farber/Harvard Cancer Center, Boston, MA

Rita Nanda, MD

Associate Professor of Medicine

Director, Breast Oncology Program

The University of Chicago Medicine Chicago, IL

his podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.

https://www.practicepointcme.com/CMEHome/talking-tnbc-advancing-treatment-in-triple-negative-breast-cancer-latest-insights-and-clinical-strategies-19